ArticleNeonatology2022
Urine Proteomics for Noninvasive Monitoring of Biomarkers in Bronchopulmonary Dysplasia.
Article in Neonatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- Preterm functional outcomes are reflected in early postnatal proteome changes.Pediatric research · 2026Article
- Qualitative assessment of nasopharyngeal aspirates as an alternative to tracheal aspirates in extremely preterm infants.Frontiers in pediatrics · 2026Article
- Transforming neonatal care through informatics: A review of artificial intelligence, data, and implementation considerations.Seminars in perinatology · 2025Review
- Proteomic Analysis of Nasopharyngeal Aspirate Biomarkers for Prematurity-Related Bronchopulmonary Dysplasia.Chest · 2025Article
- Review
- Article
- Advocating for the inclusion of kidney health outcomes in neonatal research: best practice recommendations by the Neonatal Kidney Collaborative.Journal of perinatology : official journal of the California Perinatal Association · 2024Review
- Bioinformatics in Neonatal/Pediatric Medicine-A Literature Review.Journal of personalized medicine · 2024Review
- Proteomics-Based Mapping of Bronchopulmonary Dysplasia-Associated Changes in Noninvasively Accessible Oral Secretions.The Journal of pediatrics · 2024Article
- Recent progress in mass spectrometry-based urinary proteomics.Clinical proteomics · 2024Review
- Stratification of neurogenic bladder risk in spina bifida using the urinary peptidome.American journal of physiology. Renal physiology · 2024Article
- Comparison of clean catch and bag urine using LC-MS/MS proteomics in infants.Pediatric nephrology (Berlin, Germany) · 2024Article
- Predictive analytics in bronchopulmonary dysplasia: past, present, and future.Frontiers in pediatrics · 2024Review
- Current status and future directions of application of urine proteomics in neonatology.Frontiers in pediatrics · 2024Review
- New insights into the natural history of bronchopulmonary dysplasia from proteomics and multiplexed immunohistochemistry.American journal of physiology. Lung cellular and molecular physiology · 2023Article
- Characterizing the urinary proteome of prematurity-associated lung disease in school-aged children.Respiratory research · 2023Article
- A bioinformatics approach towards bronchopulmonary dysplasia.Translational pediatrics · 2023Review
- Early prediction of bronchopulmonary dysplasia: can noninvasive monitoring methods be essential?ERJ open research · 2023Review
- Clinical Proteomics: Liquid Chromatography-Mass Spectrometry (LC-MS) Purification Systems.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Pathogenesis of Bronchopulmonary Dysplasia: Role of Oxidative Stress from 'Omics' Studies.Antioxidants (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
Abstract
introductionCurrent techniques to diagnose and/or monitor critically ill neonates with bronchopulmonary dysplasia (BPD) require invasive sampling of body fluids, which is suboptimal in these frail neonates. We tested our hypothesis that it is feasible to use noninvasively collected urine samples for proteomics from extremely low gestational age newborns (ELGANs) at risk for BPD to confirm previously identified proteins and biomarkers associated with BPD.
methodsWe developed a robust high-throughput urine proteomics methodology that requires only 50 μL of urine. We utilized the methodology with a proof-of-concept study validating proteins previously identified in invasively collected sample types such as blood and/or tracheal aspirates on urine collected within 72 h of birth from ELGANs (gestational age [26 ± 1.2] weeks) who were admitted to a single Neonatal Intensive Care Unit (NICU), half of whom eventually developed BPD (n = 21), while the other half served as controls (n = 21).
resultsOur high-throughput urine proteomics approach clearly identified several BPD-associated changes in the urine proteome recapitulating expected blood proteome changes, and several urinary proteins predicted BPD risk. Interestingly, 16 of the identified urinary proteins are known targets of drugs approved by the Food and Drug Administration.
conclusionIn addition to validating numerous proteins, previously found in invasively collected blood, tracheal aspirate, and bronchoalveolar lavage, that have been implicated in BPD pathophysiology, urine proteomics also suggested novel potential therapeutic targets. Ease of access to urine could allow for sequential proteomic evaluations for longitudinal monitoring of disease progression and impact of therapeutic intervention in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.